Skip Navigation


NDT Advance Access originally published online on September 16, 2005
Nephrology Dialysis Transplantation 2006 21(1):166-175; doi:10.1093/ndt/gfi116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/1/166    most recent
gfi116v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goldfarb-Rumyantzev, A. S.
Right arrow Articles by Cheung, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldfarb-Rumyantzev, A. S.
Right arrow Articles by Cheung, A. K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Original Articles: Dialysis and Transplantation

A crossover study of short daily haemodialysis

Alexander S. Goldfarb-Rumyantzev1, John K. Leypoldt1,2, Natalia Nelson1, Nancy G. Kutner3 and Alfred K. Cheung1,2

1 University of Utah School of Medicine, Salt Lake City, UT, USA, 2 Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA and 3 Emory University School of Medicine, Atlanta, GA, USA

Correspondence and offprint requests to: Alexander S. Goldfarb-Rumyantzev, Division of Nephrology and Hypertension, University of Utah Health Sciences Center, 85 North Medical Drive, East Rm 201, Salt Lake City, UT 84112, USA. Email: alex.goldfarb{at}hsc.utah.edu

Background. The benefits of daily haemodialysis (DHD) compared to conventional three times per week haemodialysis (CHD) have been described in a number of observational studies. Most of these previous studies however have not been performed with rigorous controls.

Methods. We performed a crossover study following an A-B-A design: phase A was 4 weeks of thrice weekly dialysis, 3–4 h per treatment (CHD); phase B was 8 weeks of six times/week dialysis, each session being one-half of the usual time (DHD) and phase A with 4 weeks of thrice weekly dialysis (CHD) was repeated. Patients characteristics: n = 12, six males; age 52±18 years, six diabetics.

Results. Weekly single-pool Kt/V, equilibrated Kt/V and standard Kt/V of urea, and ß-2-microglobulin clearance values were greater during DHD. Eight of 12 patients who completed the study reported symptomatic benefits from DHD that partially or completely disappeared during the second period of CHD. Quality of life of patients improved during DHD. Three patients had problems with arteriovenous access during DHD. Average blood pressure was lower during DHD (systolic 139.5±22.7 mmHg) compared to the initial (147.7±21.4 mmHg, P<0.001) and last (146.4±20.0 mmHg, P<0.005) CHD periods. No significant changes in predialysis haemoglobin and the serum concentration of albumin, phosphate, ß-2-microglobulin or B-type natriuretic peptides (BNP) were observed, although BNP trended downward during DHD and returned to baseline level during the second period of CHD. The dose of erythropoietin did not change significantly. Patient compliance with the dialysis schedule was lower during DHD. Dialysis staff perceived an increased workload but felt that the patients benefited medically from DHD.

Conclusions. The results of this cross-over study suggest symptomatic benefits and decrease in blood pressure, but there are potential problems with compliance and vascular access during DHD.

Keywords: blood pressure; daily haemodialysis; outcome; quality of life; quotidian haemodialysis; urea kinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Vartia
Effect of treatment frequency on haemodialysis dose: comparison of EKR and stdKt/V
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2797 - 2803.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Okuno, E. Ishimura, K. Kohno, Y. Fujino-Katoh, Y. Maeno, T. Yamakawa, M. Inaba, and Y. Nishizawa
Serum {beta}2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 571 - 577.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Punal, L. V. Lema, D. Sanhez-Guisande, and A. Ruano-Ravina
Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2634 - 2646.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. G. Achinger and J. C. Ayus
Left Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor?
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S255 - S261.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.